HemaForge RX-7 is a perfluorocarbon-hemoglobin hybrid suspension manufactured by Lazarus Pharmaceuticals that functions as a universal synthetic blood substitute capable of oxygen transport, clotting factor delivery, and immune modulation simultaneously. Unlike earlier-generation blood substitutes, the RX-7 formulation incorporates programmable nano-encapsulated clotting agents that activate via localized pH sensors, allowing the suspension to behave as normal plasma in undamaged vascular tissue while aggressively coagulating at wound sites. The suspension is shelf-stable for 18 months without refrigeration and compatible with all known human blood types, making it the logistical backbone of battlefield medicine, black-market trauma care, and corporate emergency response units throughout GLMZ.

What distinguishes the RX-7 from competitors is its secondary 'metabolic bridge' function — the suspension carries a proprietary micro-nutrient payload that sustains cellular viability in oxygen-deprived tissue for up to 40 minutes post-administration, buying critical time for surgical intervention. Helix Biosystems attempted to challenge Lazarus's patent on the pH-triggered encapsulation mechanism in 2181 and lost, cementing Lazarus's monopoly on this specific approach. The product comes in 500ml pressure-sealed ampules designed for single-handed field deployment, and in bulk 10-liter reservoir bags for clinical settings.

On the street, RX-7 is frequently diverted from Kelpline Logistics shipments destined for Tier 1 trauma centers and resold to unlicensed ripperdocs and underground combat arenas. Counterfeit versions lacking the genuine nano-encapsulation matrix circulate widely in Tier 4 and 5 districts, causing fatal clotting cascades when administered — a known problem Lazarus Pharmaceuticals has been accused of deliberately under-addressing to protect legitimate sales channels.